Famotidine (oral): Difference between revisions

Jump to navigation Jump to search
m (Protected "Famotidine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
 
(27 intermediate revisions by 2 users not shown)
Line 1: Line 1:
<small>'''''Synonyms / Brand Names:''''' Famotidina, Famotidinum, Amfamox, Antodine, Apo-Famotidine, Apogastine, Bestidine, Blocacid, Brolin, Cepal, Confobos, Cronol, Cuantin, Dibrit 40, Digervin, Dinul, Dipsin, Dispromil, Dispronil, Duovel, Durater, Evatin, Fadin, Fadine, Fadyn, Fagastine, Famo, Famocid, Famodar, Famodil, Famodin, Famodine, Famogard, Famonit, Famopsin, Famos, Famosan, Famotal, Famotep, Famotin, Famovane, Famowal, Famox, Famoxal, Famtac, Famulcer, Fanobel, Fanosin, Fanox, Farmotex, Ferotine, Fibonel, Fluxid, Fudone, Ganor, Gaster, Gastridan, Gastridin, Gastrion, Gastro, Gastrodomina, Gastrofam, Gastropen, Gastrosidin, H2 Bloc, Hacip, Huberdina, Ingastri, Invigan, Lecedil, Logos, Mensoma, Midefam, Mosul, Motiax, Muclox, Mylanta AR, Neocidine, Nevofam, Notidin, Novo-Famotidine, Nu-Famotidine, Nulceran, Nulcerin, Panalba, Pepcid, Pepcid AC, Pepcid RPD, Pepcidin, Pepcidin Rapitab, Pepcidina, Pepcidine, Pepdif, Pepdine, Pepdul, Pepfamin, Peptan, Peptidin, Peptifam, Pepzan, Purifam, Quamatel, Quamtel, Renapepsa, Restadin, Rogasti, Rubacina, Sedanium-R, Sigafam, Supertidine, Tairal, Tamin, Tipodex, Topcid, Ulcatif, Ulceprax, Ulcofam, Ulfagel, Ulfam, Ulfamid, Ulfinol, Ulgarine, Vagostal, Weimok, Whitidin, Yamarin</small>
{{DrugProjectFormSinglePage
|authorTag={{KS}}
|OTC=Yes
|genericName=famotidine (oral)
|aOrAn=a
|drugClass=gastric acid secretion inhibitor
|indicationType=treatment
|indication=[[heartburn]],gastric hypersecretion, [[gastric ulcer]],[[gastroesophageal reflux]],  
[[indigestion]]
|adverseReactions=[[constipation]] ,[[diarrhea]], [[dizziness]] , [[headache]]
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


{{CMG}}
* Content


==Dosing and Administration==
<!--Adult Indications and Dosage-->
'''Duodenal Ulcer'''
*Acute therapy: The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks; there is rarely reason to use Famotidine at full dosage for longer than 6 to 8 weeks. A regimen of 20 mg b.i.d. is also effective.
*Maintenance therapy: The recommended adult oral dose is 20 mg once a day at bedtime.
'''Benign Gastric Ulcer'''
*Acute therapy: The recommended adult oral dosage for active benign gastric ulcer is 40 mg once a day at bedtime.
For dosing and administration instructions for gastroesophageal reflux disease (GERD), dosage for pediatric patients <1 year of age with GERD, dosage for pediatric patients 1 to 16 years of age, pathological hypersecretory conditions, oral suspension, orally disintegrating tablets, concomitant use of antacids, and dosage adjustment for patients with moderate or severe renal insufficiency see [[{{PAGENAME}} instructions for administration|Instructions for Administration]].
<br>
----
<br>
<font size="4">
[[{{PAGENAME}}#FDA Package Insert Resources|FDA Package Insert Resources]]
<br></font size><small>Indications, Contraindications, Side Effects, Drug Interactions, etc.</small><font size="4"><br>
<br>
[http://www.pace-med-apps.com/gfrcalc.htm Calculate Creatine Clearance]
<br></font size><small>On line calculator of your patients Cr Cl by a variety of formulas.</small><font size="4"><br>
<br>
[http://home.earthlink.net/~sensei11/convert.htm Convert pounds to Kilograms]
<br></font size><small>On line calculator of your patients weight in pounds to Kg for dosing estimates.</small><font size="4"><br>
<br> [[{{PAGENAME}}#Publication Resources|Publication Resources]]
<br></font size><small>Recent articles, WikiDoc State of the Art Review, Textbook Information</small><font size="4"><br>
<br>
[[{{PAGENAME}}#Trial Resources|Trial Resources]]
<br></font size><small>Ongoing Trials, Trial Results</small><font size="4"><br>
<br>
[[{{PAGENAME}}#Guidelines & Evidence Based Medicine Resources|Guidelines & Evidence Based Medicine Resources]]
<br></font size><small>US National Guidelines, Cochrane Collaboration, etc.</small><font size="4"><br>
<br>
[[{{PAGENAME}}#Media Resources|Media Resources]]
<br></font size><small>Slides, Video, Images, MP3, Podcasts, etc.</small><font size="4"><br><br>
[[{{PAGENAME}}#Patient Resources|Patient Resources]]
<br></font size><small>Discussion Groups, Handouts, Blogs, News, etc.</small><font size="4"><br>
<br>
[[{{PAGENAME}}#International Resources|International Resources]]
<br></font size><small>en Español</small><font size="4"><br>
<br>
----
<br>
<br>
<br>
<br>


==FDA Package Insert Resources==
<!--FDA-Labeled Indications and Dosage (Adult)-->
[[{{PAGENAME}} indications|Indications]]
|fdaLIADAdult===Indications==
<br>
<br>
[[{{PAGENAME}} contraindications|Contraindications]]
<br>
<br>
[[{{PAGENAME}} side effects|Side Effects]]
<br>
<br>
[[{{PAGENAME}} drug interactions|Drug Interactions]]
<br>
<br>
[[{{PAGENAME}} precautions|Precautions]]
<br>
<br>
[[{{PAGENAME}} overdose|Overdose]]
<br>
<br>
[[{{PAGENAME}} instructions for administration|Instructions for Administration]]
<br>
<br>
[[{{PAGENAME}} how supplied|How Supplied]]
<br>
<br>
[[{{PAGENAME}} pharmacokinetics and molecular data|Pharmacokinetics and Molecular Data]]
<br>
<br>
[http://www.fda.gov/cder/foi/label/2001/20752s6lbl.pdf FDA label]
<br>
<br>
[http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


==Publication Resources==
* [[Duodenal ulcer]]  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most Recent Articles on {{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}]
* Esophagitis - [[gastroesophageal reflux]] disease,  
<br>
* Gastric hypersecretion
<br>
* [[Gastric ulcer]]
[http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D  Review Articles on {{PAGENAME}}]
* [[Gastroesophageal reflux]] disease
<br>
* [[Indigestion]]
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28%28N+Engl+J+Med%5Bta%5D%29+OR+%28Lancet%5Bta%5D%29+OR+%28BMJ%5Bta%5D%29%29 Articles on {{PAGENAME}} in N Eng J Med, Lancet, BMJ]
<br>
<br>
[[{{PAGENAME}} detailed information|WikiDoc State of the Art Review]]
<br>
<br>
[http://books.google.com/books?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=gp Textbook Information on {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


==Trial Resources==
==Dosing==
[http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials with {{PAGENAME}} at Clinical Trials.gov]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28randomized+controlled+trial%5BPublication+Type%5D+OR+%28randomized%5BTitle%2FAbstract%5D+AND+controlled%5BTitle%2FAbstract%5D+AND+trial%5BTitle%2FAbstract%5D%29%29 Trial Results with {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


==Guidelines & Evidence Based Medicine Resources==
* To relieve symptoms, swallow 1 tablet with a glass of water. Do not chew.
[http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse on {{PAGENAME}}]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cochrane Database Syst Rev[ta])}} Cochrane Collaboration on {{PAGENAME}}]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cost effectiveness)}} Cost Effectiveness of {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
==Media Resources==
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint Slides on {{PAGENAME}}]
<br>
<br>
[http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images of {{PAGENAME}}]
<br>
<br>
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=hPo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+podcasts+OR+MP3&btnG=Search Podcasts & MP3s on {{PAGENAME}}]
<br>
<br>
[http://video.google.com/videosearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&um=1&sa=N&tab=fv# Videos on {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


==Patient Resources==
* To prevent symptoms, swallow 1 tablet with a glass of water at any time from 10 to 60 minutes before eating food or drinking beverages that cause heartburn
[[{{PAGENAME}} (patient information)|Patient Information from National Library of Medicine]]
<br>
<br>
[http://www.google.com/search?hl=en&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:for_patients&cx=disease_for_patients&sa=N&oi=cooptsr&resnum=0&ct=col3&cd=1  Patient Resources on {{PAGENAME}}]
<br>
<br>
[http://groups.google.com/groups/search?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search Discussion Groups on {{PAGENAME}}]
<br>
<br>
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:patient_handouts&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col1&cd=3 Patient Handouts on {{PAGENAME}}]
<br>
<br>
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]
<br>
<br>
[http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the News]
<br>
<br>
[http://finance.google.com/finance?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=te {{PAGENAME}} in the Marketplace]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


==International Resources==
* Do not use more than 2 tablets in 24 hours
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+en+espanol&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a {{PAGENAME}} en Español]
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of famotidine in adult patients.
<br>
|offLabelAdultNoGuideSupport===Indications==
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
</font size>
----
{{FDA}}


[[Category:Drugs]]
* Esophagitis, Maintenance
* [[Gastritis]]
* [[Gastrointestinal hemorrhage]]
* [[Stress ulcer]]
* [[Urticaria]]
 
==Dosing==
 
* Duodenal ulcer disease: acute, 40 mg orally once daily at bedtime or 20 mg orally twice daily
* Duodenal ulcer disease: maintenance, 20 mg orally once daily at bedtime
 
* Esophagitis - Gastroesophageal reflux disease, Short term treatment: 20 to 40 mg orally twice daily for up to 12 weeks
 
* Gastric hypersecretion: 20 to 160 mg orally every 6 h.
 
* Gastric ulcer, Short term treatment: acute, 40 mg orally once daily at bedtime
 
* Gastroesophageal reflux disease, Short-term, symptom treatment: 20 mg orally twice daily for up to 6 wks
 
* Indigestion: 10 to 20 mg orally twice daily
|fdaLIADPed===Indication==
 
* [[Duodenal ulcer]]
* Esophagitis - [[gastroesophageal reflux]] disease,
* Gastric hypersecretion
* [[Gastric ulcer]]
* [[Gastroesophageal reflux]] disease
* [[Indigestion]]
 
==Dosing==
 
'''Children 12 years and over''':
 
* To relieve symptoms, swallow 1 tablet with a glass of water. Do not chew.
 
* To prevent symptoms, swallow 1 tablet with a glass of water at any time from 10 to 60 minutes before eating food or drinking beverages that cause heartburn
 
* Do not use more than 2 tablets in 24 hours
 
Children under 12 years: ask a doctor
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Famotidine in pediatric patients.
|offLabelPedNoGuideSupport===Indications==
* [[Stress ulcer]]; Prophylaxis
 
==Dosage==
* Duodenal ulcer disease: (over 1 y old) 0.5 mg/kg/day orally at bedtime or divided twice daily; max dose 40 mg/day
 
* Gastric ulcer, Short term treatment: (over 1 y old) 0.5 mg/kg/day orally at bedtime or divided twice daily; max dose 40 mg/day
|warnings='''Allergy alert''': Do not use if you are allergic to famotidine or other acid reducers
 
'''Do not use'''
 
if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools. These may be signs of a serious condition. See your doctor.
if you have kidney disease, except under the advice and supervision of a doctor
with other acid reducers
 
'''Ask a doctor before use if you have'''
 
* Had heartburn over 3 months. This may be a sign of a more serious condition.
 
* Heartburn with [[lightheadedness]], sweating, or [[dizziness]]
 
* [[Chest pain]] or shoulder pain with [[shortness of breath]]; sweating; pain spreading to arms, neck or shoulders; or [[lightheadedness]]
 
* Frequent chest pain
 
* Frequent wheezing, particularly with heartburn
 
* Unexplained weight loss
 
* [[Nausea]] or [[vomiting]]
* Stomach pain
 
'''Stop use and ask a doctor if'''
 
* Your heartburn continues or worsens
* You need to take this product for more than 14 days
 
'''If pregnant or breast-feeding''',
 
* Ask a health professional before use.
 
'''Keep out of reach of children'''.
 
* In case of overdose, get medical help or contact a Poison Control Center right away.
|clinicalTrials='''Common'''
* Gastrointestinal: [[constipation]], [[diarrhea]]
* Neurologic: [[dizziness]], [[headache]]
 
'''Serious'''
* Dermatologic: [[Stevens-Johnson syndrome]] (very rare ), toxic epidermal necrolysis (very rare )
* Gastrointestinal: necrotizing enterocolitis in fetus OR newborn
* Immunologic: [[anaphylaxis]] (infrequent ), [[angioedema]] (infrequent )
* Musculoskeletal: [[rhabdomyolysis]]
* Neurologic: [[seizure]] (rare )
* Respiratory: [[Interstitial pneumonia]] (infrequent ), [[nosocomial pneumonia]]
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Famotidine in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of Famotidine during labor and delivery.
|useInNursing=There is no FDA guidance on the use of Famotidine  with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of Famotidine with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of Famotidine  with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of  Famotidine with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of Famotidine with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of Famotidine in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of Famotidine in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of Famotidine in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of Famotidine in patients who are immunocompromised.
|administration=* Oral
|monitoring=There is limited information regarding <i>Monitoring</i> of Famotidine in the drug label.
 
 
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of Famotidine in the drug label.
|overdose=There is limited information regarding <i>Chronic Overdose</i> of Famotidine in the drug label.
|drugBox=[[File:Famotidine structure.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
|PD=There is limited information regarding <i>Pharmacodynamics</i> of  in the drug label.
|PK=There is limited information regarding <i>Pharmacokinetics</i> of Famotidine in the drug label.
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of Famotidine in the drug label.
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of Famotidine in the drug label.
|storage=* Store at 20°-25°C (68°-77°F)
* Protect from moisture and light
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of Famotidine in the drug label.
|alcohol=* Alcohol-Famotidine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|brandNames=* 7 SELECT ACID CONTROLLER
|drugShortage=
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName=Famotidine fig01.jpg
}}
{{LabelImage
|fileName=Famotidine ingredients and appearance.png
}}
{{LabelImage
|fileName=Famotidine fig.jpg
}}
<!--Pill Image-->
 
 
 
<!--Label Display Image-->
 
 
 
 
 
<!--Category-->
[[Category:Guanidines]]
[[Category:Drug]]

Latest revision as of 14:21, 11 May 2015

Famotidine (oral)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Famotidine (oral) is a gastric acid secretion inhibitor that is FDA approved for the treatment of heartburn,gastric hypersecretion, gastric ulcer,gastroesophageal reflux, indigestion. Common adverse reactions include constipation ,diarrhea, dizziness , headache.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Dosing

  • To relieve symptoms, swallow 1 tablet with a glass of water. Do not chew.
  • To prevent symptoms, swallow 1 tablet with a glass of water at any time from 10 to 60 minutes before eating food or drinking beverages that cause heartburn
  • Do not use more than 2 tablets in 24 hours

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of famotidine in adult patients.

Non–Guideline-Supported Use

Indications

Dosing

  • Duodenal ulcer disease: acute, 40 mg orally once daily at bedtime or 20 mg orally twice daily
  • Duodenal ulcer disease: maintenance, 20 mg orally once daily at bedtime
  • Esophagitis - Gastroesophageal reflux disease, Short term treatment: 20 to 40 mg orally twice daily for up to 12 weeks
  • Gastric hypersecretion: 20 to 160 mg orally every 6 h.
  • Gastric ulcer, Short term treatment: acute, 40 mg orally once daily at bedtime
  • Gastroesophageal reflux disease, Short-term, symptom treatment: 20 mg orally twice daily for up to 6 wks
  • Indigestion: 10 to 20 mg orally twice daily

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Indication

Dosing

Children 12 years and over:

  • To relieve symptoms, swallow 1 tablet with a glass of water. Do not chew.
  • To prevent symptoms, swallow 1 tablet with a glass of water at any time from 10 to 60 minutes before eating food or drinking beverages that cause heartburn
  • Do not use more than 2 tablets in 24 hours

Children under 12 years: ask a doctor

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Famotidine in pediatric patients.

Non–Guideline-Supported Use

Indications

Dosage

  • Duodenal ulcer disease: (over 1 y old) 0.5 mg/kg/day orally at bedtime or divided twice daily; max dose 40 mg/day
  • Gastric ulcer, Short term treatment: (over 1 y old) 0.5 mg/kg/day orally at bedtime or divided twice daily; max dose 40 mg/day

Contraindications

There is limited information regarding Famotidine (oral) Contraindications in the drug label.

Warnings

Allergy alert: Do not use if you are allergic to famotidine or other acid reducers

Do not use

if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools. These may be signs of a serious condition. See your doctor. if you have kidney disease, except under the advice and supervision of a doctor with other acid reducers

Ask a doctor before use if you have

  • Had heartburn over 3 months. This may be a sign of a more serious condition.
  • Frequent chest pain
  • Frequent wheezing, particularly with heartburn
  • Unexplained weight loss

Stop use and ask a doctor if

  • Your heartburn continues or worsens
  • You need to take this product for more than 14 days

If pregnant or breast-feeding,

  • Ask a health professional before use.

Keep out of reach of children.

  • In case of overdose, get medical help or contact a Poison Control Center right away.

Adverse Reactions

Clinical Trials Experience

Common

Serious

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Famotidine (oral) in the drug label.

Drug Interactions

There is limited information regarding Famotidine (oral) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Famotidine (oral) in women who are pregnant.
Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Famotidine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Famotidine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Famotidine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Famotidine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Famotidine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Famotidine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Famotidine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Famotidine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Famotidine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Famotidine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Famotidine in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral

Monitoring

There is limited information regarding Monitoring of Famotidine in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Famotidine in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Famotidine in the drug label.

Pharmacology

This image is provided by the National Library of Medicine.

Mechanism of Action

There is limited information regarding Famotidine (oral) Mechanism of Action in the drug label.

Structure

There is limited information regarding Famotidine (oral) Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Famotidine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Famotidine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Famotidine in the drug label.

How Supplied

There is limited information regarding Famotidine (oral) How Supplied in the drug label.

Storage

  • Store at 20°-25°C (68°-77°F)
  • Protect from moisture and light

Images

Drug Images

{{#ask: Page Name::Famotidine (oral) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Famotidine (oral) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Famotidine in the drug label.

Precautions with Alcohol

  • Alcohol-Famotidine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • 7 SELECT ACID CONTROLLER

Look-Alike Drug Names

There is limited information regarding Famotidine (oral) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Famotidine (oral)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Famotidine (oral)
 |Label Name=Famotidine fig01.jpg

}}

{{#subobject:

 |Label Page=Famotidine (oral)
 |Label Name=Famotidine ingredients and appearance.png

}}

{{#subobject:

 |Label Page=Famotidine (oral)
 |Label Name=Famotidine fig.jpg

}}